Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results | Onconova Therapeutics
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition | Onconova Therapeutics
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock | Onconova Therapeutics
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit | Onconova Therapeutics
Onconova Therapeutics Announces Termination of Proposed Public Offering | Onconova Therapeutics
Learn about your clients' org charts. Understand their industries and their competitors.
View the executives' biographies. Contact the executives through our email platform.
Select key words to follow your clients. Receive alerts when executive movements happen.
File your clients in folders. Add private notes. Download our data in Excel on your PC.